Post by
Viking2233 on Aug 09, 2023 12:48pm
No Volume
Well back from vacation, does not look like I missed anything. Still no third party peer review on phase 2. The last 3 press releases were solid and very positive. I am flabbergasted that we never got a big lift but we are in a tough market with high interest rates, inflation concerns, so lots of money ditting on the sidelines.
I am personally perplexed as to what it will take to get buyers in here and in particular institutional money. I have looked at several similar staged companies and it is obvious that we are severely undervalued at $135M market cap compared to peers ar $800M to $5B at similar stage. There are two points that stick out to me. The fact we are on the TSXV would be an isdue for many institutional investors, tge lack of volume and liquidity is another and finally our share price and market cap are below the thresholds that many institutional investors must comply with.
Arch currently has 0% Institutional investors where most of the similar staged peers are 15-35% Institutional ownership.
I am not sure how management intends to stick handle this but they have two key strategic advisors with strong ties and connections to big pharma.
I continue to patiently hold this while we wait for the FDA approved AKI phase 2 study to commence in the fall. My gut tells me if the results from phase 2 are stellar which I see no readon why they wont considering past trials plus now they can use a higher dose, we may have a opportunity to be fast tracked.